Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA
July 29, 2024 08:30 ET
|
Vivos Inc.
Richland WA, July 29, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Provides IDE Submission Status Update The FDA has been working diligently to review the extensive amount of...
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
June 28, 2024 10:15 ET
|
Vivos Inc.
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing...
Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation
December 20, 2023 10:08 ET
|
Vivos Inc.
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy...
Vivos Inc. Announces Certification of Three New IsoPet® Precision Radionuclide Therapy Regional Clinics
August 07, 2023 09:30 ET
|
Vivos Inc.
Richland WA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that it certified three additional clinics to offer Isopet® Precision Radionuclide Therapy...
Vivos Inc Files a New Patent on the Hydrogel Component of IsoPet®/RadioGel™
September 14, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a patent application on their hydrogel component of IsoPet/RadioGel in the USA...
Vivos Inc. Announces a New IsoPet® Precision Radionuclide Therapy Regional Clinic for Equine Therapy
August 16, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it just certified the New England Equine Practice in Patterson, NY to administer...
Vivos Inc Implements Multiple Patient IsoPet® Therapy Day
April 21, 2022 09:30 ET
|
Vivos Inc.
Richland WA, April 21, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce a combined IsoPet® therapy schedule into one treatment day, allowing for one production run...
Vivos Inc. Enhances its Intellectual Property Protection
February 24, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it filed its particle patent in several countries. Our new patent team filed the...
Vivos Inc Obtains Feedback from the FDA on Clinical Testing of RadioGel™
December 02, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), on November 30 Vivos Inc met with the Food and Drug Administration to obtain suggestions on improving the current draft of...
Vivos Inc Announces Johns Hopkins University (Veterinary Clinical Trials Network) is a New Regional Clinic for Isopet®
November 23, 2021 09:30 ET
|
Vivos Inc.
This replaces and corrects the press release from November 22. Johns Hopkins (VCTN) Veterinary Clinical Trials Network is our teaming partner not the Center for Image Guided Animal Therapy (CIGAT). ...